

L63 - LPL Sagar



Vandana Lal Dr. Vandana Lal M.D (PATH), IFCAP Chief of Pathology

el Dentado De Sal Paralado De Sal Paralado De Las Paralado De Sal Paralado De Sal Paralado D	and President to the Residents to dest President to day?
Name : Mrs. SUNITA SHUKLA	Collected : 24/2/2018 9:28:00AM
De Les Persides De Les Pers	Received : 24/2/2018 9:37:08AM
Lab No. : 247715836 Age: 52 Years Gender: Female	Reported : 27/2/2018 4:40:38PM
A/c Status P Ref By : Dr. ANKIT JAIN	Report Status : Final

Test Name	Results	Units	Bio. Ref. Interval
ANTI NUCLEAR ANTIBODY / FACTOR (ANA/ANF), SERUM @	>169.00	Units	<20.00
(EIA)			

#### Interpretation

ļ	RESULT IN UNITS	REMARKS
ļ	<20	Negative
ļ	20-60	Moderate positive
İ	>60	Strong positive

# Comments

Antinuclear antibodies are the most sensitive screening test for autoantibodies in patients suspected of connective tissue diseases. They are a heterogenous group of autoantibodies directed against ds-DNA, histones, SSA / Ro, SSB / La, Sm, Sm / RNP, Scl-70, Jo-1 & Centromere. ANA 's have also been detected in patients with Autoimmune Hepatitis (80%),Primary biliary cirrhosis (60%), Alcohol related liver disease (50%), Viral hepatitis B (40%). Presence of ANA has also been detected in individuals taking certain drugs like Hydrallazine, Isoniazid, Chlorpromazine; family of SLE patients; healthy and elderly persons

SSA/Ro ANTIBODY, SERUN (EIA)	@	153.76	Units	<20.00
Interpretation				
RESULT IN UNITS	REMARKS			
<20	Negative			
20-39	Weak Positive			
40-80	Moderate Positive			

### Comments

>80

Patients with SLE may have antibodies to SSA/Ro alone or may have both SSA/Ro & SSB/La antibodies. Presence of SSA/Ro antibody alone is commonly seen in association with HLA DR2 in patients less than 22 years of age at onset. Presence of both SSA/Ro & SSB/La in SLE is associated with HLA DR3 and is seen in older patients more than 50 years of age at onset. SLE patients with SSA/Ro antibodies develop a much more serious renal disease and have a higher incidence of concomitant Anti DNA antibodies.

Strong Positive



Page 1 of 4



L63 - LPL Sagar



Vandana Lal Dr. Vandana Lal M.D (PATH), IFCAP Chief of Pathology

	1115 115 111	A ALT WALK A ALT WALK
Name : Mrs. SUNITA SHUKLA	Collected	: 24/2/2018 9:28:00AM
De La Particle De La Par	Received	: 24/2/2018 9:37:08AM
Lab No. : 247715836 Age: 52 Years Gender: Female	Reported	: 27/2/2018 4:40:38PM
A/c Status : P Ref By : Dr. ANKIT JAIN	Report Status	: Final

Test Name	Results	Units	Bio. Ref. Interval
Increased levels			
Subacute cutaneous Lupus erythematosus			
Neonatal Lupus erythematosus syndrome v	with congenital hea	art block and cutaneous le	esions
Homozygous C2 & C4 deficiency with SLE	like disease		

- Primary Sjogren's syndrome vasculitis, Rheumatoid factor positivity & severe systemic symptoms
- ANA negative SLE patients
- SLE with Interstitial pneumonitis

SSB/La ANTIBODY, SERUM @ (EIA)	118.93	Units	<20.00
Interpretation			

REMARKS
Negative
Weak Positive
Moderate Positive
Strong Positive

#### Comments

SSB/La antibodies are primarily considered as a serological marker of Primary Sjogren's syndrome and are detected in nearly 90% of these patients. They are also seen in 6-15% cases of ANA positive SLE patients. Presence of both SSB / La & SSA/Ro antibodies in SLE patients shows a lower incidence of renal disease and lower levels of concomitant Anti DNA antibodies. Detection of this antibody can precede the development of symptoms of Sicca syndrome by several years.



Page 2 of 4



L63 - LPL Sagar



Vandana Lal Dr. Vandana Lal M.D (PATH), IFCAP Chief of Pathology

Production To Ad Products To Ad Product To Ad Products To Ad Products To Ad Products	the star threaded in the the the thread in the Souther the South
Name : Mrs. SUNITA SHUKLA	Collected : 24/2/2018 9:28:00AM
	Received : 24/2/2018 9:37:08AM
Lab No. : 247715836 Age: 52 Years Gender: Female	Reported : 27/2/2018 4:40:38PM
A/c Status : P Ref By : Dr. ANKIT JAIN	Report Status : Final

Test Name	Results	Units	Bio. Ref. Interval
THYROID PROFILE, TOTAL, SERUM (CLIA)			
T3, Total	0.84	ng/mL	0.60 - 1.81
T4, Total	6.80	ug/dL	5.01 - 12.45
TSH	11.13	ulU/mL	0.35 - 5.50

### Interpretation

PREGNANCY	REFERENCE RANGE for TSH IN uIU/mL (As per American Thyroid Association)
1st Trimester	0.10-2.50
2nd Trimester	0.20-3.00
3rd Trimester	0.30-3.00

### Note


- 1. TSH levels are subject to circadian variation, reaching peak levels between 2 4.a.m. and at a minimum between 6-10 pm . The variation is of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.
- 2. Recommended test for T3 and T4 is unbound fraction or free levels as it is metabolically active.
- 3. Physiological rise in Total T3 / T4 levels is seen in pregnancy and in patients on steroid therapy.

## **Clinical Use**

- Primary Hypothyroidism
- Hyperthyroidism
- Hypothalamic Pituitary hypothyroidism
- Inappropriate TSH secretion
- Nonthyroidal illness
- Autoimmune thyroid disease
- Pregnancy associated thyroid disorders
- Thyroid dysfunction in infancy and early childhood



Page 3 of 4



**Test Name** 

Ritu

Dr. Ritu Navar MD (Microbiology) Deputy HOD Microbiology & Serology -NRL

Shalath Malik

Dr. Shalabh Malik MD (Microbiology) National Head - Microbiology & Serology - NRL

---End of report -

Dr. Kiran Bhargava Pathak

MBBS, MD(PATH) Chief of Lab



Page 4 of 4



L63 - LPL Sagar



Vandana Lal Dr. Vandana Lal M.D (PATH), IFCAP Chief of Pathology

The seal Product of a	The second state of the	AND INCOMENTS AND INCOMENTS AND AND	MARIO LADIELA	D. C. D. M. C. D. L. D. M. L.
Name :	Mrs. SUNITA	SHUKLA	Collected	: 21/9/2018 8:39:00AM
			Received	: 21/9/2018 8:55:21AM
Lab No.	255899930	Age: 52 Years Gender: Female	Reported	: 25/9/2018 6:04:19PM
A/c Status :	P	Ref By : SELF	Report Status	: Final

Test Name	Results	Units	Bio. Ref. Interval
SWASTHFIT SUPER 2 PACKAGE			
HbA1c (GLYCOSYLATED HEMOGLOBIN), BLOOD (HPLC)	6.1	%	

### Interpretation

As per American	Diabetes Association (ADA)
Reference Group	HbA1c in %
Non diabetic adults >=18 years	<5.7
At risk (Prediabetes)	5.7 - 6.4
Diagnosing Diabetes	>= 6.5
Therapeutic goals for glycemic control	Age > 19 years . Goal of therapy: < 7.0 . Action suggested: > 8.0
	Age < 19 years . Goal of therapy: <7.5

Note: 1. Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who is recently under good control may still have a high concentration of HbA1c. Converse is true for a diabetic previously under good control but now poorly controlled .

 Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targeting a goal of < 7.0 % may not be appropriate.</li>

## Comments

HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.

# ADA criteria for correlation between HbA1c & Mean plasma glucose levels

	HbA1c(%)	Mean	Plasma	Glucose	(mg/dL)
	6	126			
	7	154			



Page 1 of 6



Units

L63 - LPL Sagar



Vandana Lal Dr. Vandana Lal M.D (PATH), IFCAP Chief of Pathology

Bio. Ref. Interval

Name : Mrs. SUNITA SHUKLA	Collected : 21/9/2018 8:39:00AM
Lab No. : 255899930 Age: 52 Years Gender: Female	Received : 21/9/2018 8:55:21AM   Reported : 25/9/2018 6:04:19PM
A/c Status : P Ref By : SELF	Report Status Final

#### Test Name

1	Results	
8	183	-
9	212	
10	240	
11	269	
12	298	



Page 2 of 6



L63 - LPL Sagar



Vandana Lal Dr. Vandana Lal M.D (PATH), IFCAP Chief of Pathology

ha <mark> Printe da Da des Printe da</mark> D	The sea Printed, The Sea Printed, The Sea Printed De Sea Print
Name : Mrs. SUNITA SHUKLA	Collected : 21/9/2018 8:39:00AM
1. De Les Particule De Les Particules De Les Particule De Les Particules De Les Particules De Les Particules De	Received : 21/9/2018 8:55:21AM
Lab No. : 255899930 Age: 52 Years Gender: Female	Reported : 25/9/2018 6:04:19PM
A/c Status : P Ref By : SELF	Report Status : Final Control

Test Name	Results	Units	Bio. Ref. Interval
THYROID PROFILE, TOTAL, SERUM (CLIA)			
T3, Total	1.18	ng/mL	0.60 - 1.81
T4, Total	9.40	ug/dL	5.01 - 12.45
TSH	4.05	uIU/mL	0.35 - 5.50

### Interpretation

PREGNANCY	REFERENCE RANGE for TSH IN uIU/mL   (As per American Thyroid Association)
1st Trimester	0.10-2.50
2nd Trimester	0.20-3.00
3rd Trimester	0.30-3.00

# Note

- 1. TSH levels are subject to circadian variation, reaching peak levels between 2 4.a.m. and at a minimum between 6-10 pm. The variation is of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.
- 2. Recommended test for T3 and T4 is unbound fraction or free levels as it is metabolically active.
- 3. Physiological rise in Total T3 / T4 levels is seen in pregnancy and in patients on steroid therapy.

# **Clinical Use**

- Primary Hypothyroidism
- Hyperthyroidism
- Hypothalamic Pituitary hypothyroidism
- Inappropriate TSH secretion
- Nonthyroidal illness
- Autoimmune thyroid disease
- Pregnancy associated thyroid disorders
- Thyroid dysfunction in infancy and early childhood



Page 3 of 6



L63 - LPL Sagar



Vandana Lal Dr. Vandana Lal M.D (PATH), IFCAP Chief of Pathology

Printed De La Printed	De ses Printede De Ses Rentedes De Ses Printedes De Ses
Name : Mrs. SUNITA SHUKLA	Collected : 21/9/2018 8:39:00AM
Lab No. : 255899930 Age: 52 Years Gender: Female	Received : 21/9/2018 8:55:21AM
Presidente Der des Presidentes	Reported : 25/9/2018 6:04:19PM
A/c Status : P Ref By : SELF	Report Status : Final

Test Name	Results	Units	Bio. Ref. Interval
ANTI NUCLEAR ANTIBODY / FACTOR (ANA/ANF), SERUM @	195.82	Units	<20.00
(EIA)			

#### Interpretation

	RESULT IN UNITS	REMARKS
ļ	<20	Negative
ļ	20-60	Moderate positive
İ	>60	Strong positive

### Comments

Antinuclear antibodies are the most sensitive screening test for autoantibodies in patients suspected of connective tissue diseases. They are a heterogenous group of autoantibodies directed against ds-DNA, histones, SSA / Ro, SSB / La, Sm, Sm / RNP, Scl-70, Jo-1 & Centromere. ANA 's have also been detected in patients with Autoimmune Hepatitis (80%),Primary biliary cirrhosis (60%), Alcohol related liver disease (50%), Viral hepatitis B (40%). Presence of ANA has also been detected in individuals taking certain drugs like Hydrallazine, Isoniazid, Chlorpromazine; family of SLE patients; healthy and elderly persons

SSA/Ro ANTIBODY, SERUM @ (EIA)	125.40	Units	<20.00
Interpretation			

RESULT IN UNITS	REMARKS
<20	Negative
20-39	Weak Positive
40-80	Moderate Positive
>80	Strong Positive

# Comments

Patients with SLE may have antibodies to SSA/Ro alone or may have both SSA/Ro & SSB/La antibodies. Presence of SSA/Ro antibody alone is commonly seen in association with HLA DR2 in patients less than 22 years of age at onset. Presence of both SSA/Ro & SSB/La in SLE is associated with HLA DR3 and is seen in older patients more than 50 years of age at onset. SLE patients with SSA/Ro antibodies develop a much



Page 4 of 6



L63 - LPL Sagar



Vandana Lat Dr. Vandana Lal M.D (PATH), IFCAP Chief of Pathology

Name :	Mrs. SUNITA	SHUKLA			Collected	: 21/9/2018	8:39:00AM
	De Lat Particula De			Late Da Lat Par	Received	: 21/9/2018	8:55:21AM
Lab No.	255899930	Age: 52 Years	Gender:	Female	Reported	: 25/9/2018	6:04:19PM

Test NameResultsUnitsmore serious renal disease and have a higher incidence of concomitant Anti DNA antibodies.

Bio. Ref. Interval

Increased levels

- Subacute cutaneous Lupus erythematosus
- Neonatal Lupus erythematosus syndrome with congenital heart block and cutaneous lesions
- Homozygous C2 & C4 deficiency with SLE like disease
- Primary Sjogren's syndrome vasculitis, Rheumatoid factor positivity & severe systemic symptoms
- ANA negative SLE patients
- SLE with Interstitial pneumonitis

SSB/La ANTIBODY, SERUM @	95.20	Units	<20.00
(EIA)			

# Interpretation

RESULT IN UNITS   REMARKS
<pre>&lt;20 Negative</pre>
20-39 Weak Positive
40-80   Moderate Positive
>80   Strong Positive

# Comments

SSB/La antibodies are primarily considered as a serological marker of Primary Sjogren's syndrome and are detected in nearly 90% of these patients. They are also seen in 6-15% cases of ANA positive SLE patients. Presence of both SSB / La & SSA/Ro antibodies in SLE patients shows a lower incidence of renal disease and lower levels of concomitant Anti DNA antibodies. Detection of this antibody can precede the development of symptoms of Sicca syndrome by several years.

Dr. Anil Arora MD (Pathology) HOD Hemat & Imm - NRL

Dr. Kiran Bhargava Pathak MBBS, MD(PATH) Chief of Lab



Page 5 of 6



L63 - LPL Sagar



Vandana Lal Dr. Vandana Lal M.D (PATH), IFCAP Chief of Pathology

e Parente De La Parente De La Parente De La Parente De La Parente De La Parente I	De die Preside De die Preside De die Presiden De die 2
Name : Mrs. SUNITA SHUKLA	Collected : 21/9/2018 8:39:00AM
De La Paul Lab De La Paul Lab De La Paul Lab De La Paul Lab De La Paul Lab De La Paul	Received : 21/9/2018 8:55:21AM
Lab No. : 255899930 Age: 52 Years Gender: Female	Reported : 25/9/2018 6:04:19PM
A/c Status : P Ref By : SELF	Report Status : Final

**Test Name** 

Results

Units

Bio. Ref. Interval

-----End of report -----

#### **IMPORTANT INSTRUCTIONS**

\*Test results released pertain to the specimen submitted.\*All test results are dependent on the quality of the sample received by the Laboratory. \*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .\*Sample repeats are accepted on request of Referring Physician within 7 days post reporting.\*Report delivery may be delayed due to unforeseen circumstances. Inconvenience is regretted.\*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit request within 72 hours post reporting.\*Test results may show interlaboratory variations.\*The Courts/Forum at Delhi shall have exclusive jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).\*Test results are not valid for medico legal purposes. \*Contact customer care Tel No. +91-11-39885050 for all queries related to test results.



Page 6 of 6

g Dr Lal	PathLabs
----------	----------

L63 - LPL Sagar GROUND FLOOR,IN FRONT OF BUNDELKHAND MEDICAL COLLEGE, TILLI, NEAR GOUTAM TRADERS, SAGAR (M-P) 470001		Hwille (Hony) Brig. Dr. Arvind Lal M.B.B.S., D.C.P. Padma Shri FMR HONORARY PRESENT OF INDIA	Vandana Lat Dr. Vandana Lat M.D (PXTH), IFCAP Chief of Pathology SHIROMAN AWARD WIRNER		
	n de Penden De Sel Penden De de Penden De de Pen 1941 De de Penden De de Penden De de Penden De d	ilada Da Lat Partileda Da Lat Partileda i A Partileda Da Lat Partileta Da Lat Par	De Las Participado De Lo Alado De Las Participad	et Particula De Lat Particula De Lat e De Lat Particula De Lat Particula	
	Name : MRS. SUNITA SHUKLA		Collected	: 21-9-2018 08:39 AM	
	Les Probleds De Les Publiches De Les Pethicks De Les Park		Received	: 21-9-2018 10:58 AM	
	Lab No. : 255899930 Age : 52 Yrs.	Gender : Female	Reported	: 21-9-2018 01:37 PM	
	A/c Status : Ref By: SELF ,	Leho Da Let Particula Da Let Particula ( 18 Particulas Da Let Particula (Da Let Par	Report Status	: Final	
	Test Name	Results	Units	Bio. Ref. Interval	
	ERYTHROCYTE SEDIMENTATION RATE ;ESR (Westergren)	28	mm/hr	< 30.00	
	Note				
	1 C Papetivo Protoin (CPP) is the recommo	nded test in soute inflammate	ny conditions		

1. C-Reactive Protein (CRP) is the recommended test in acute inflammatory conditions.

2. Test conducted on EDTA whole blood.

C-REACTIVE PROTEIN; CRP, SERUM	Positive
(ICT)	

# Comments

CRP is an acute phase reactant which is used in inflammatory disorders for monitoring course and effect of therapy. It is most useful as an indicator of activity in Rheumatoid arthritis, Rheumatic fever, tissue injury or necrosis and infections. As compared to ESR, CRP shows an earlier rise in inflammatory disorders which begins in 4-6 hrs, the intensity of the rise being higher than ESR and the recovery being earlier than ESR. Unlike ESR, CRP levels are not influenced by hematologic conditions like Anemia, Polycythemia etc.

Dr.Surendra.K.Singh Chief of Lab M.D. patho

Page 1 of 4

# Dr Lal PathLabs

L63 - LPL Sagar **GROUND FLOOR, IN FRONT** BUNDELKHAND OF MEDICAL COLLEGE, TILLI, NEAR GOUTAM TRADERS , SAGAR (



Vandana Lal Dr. Vandana Lal M.D (PATH), IFCAP Chief of Pathology

SAGAR ( M-P ) 470001	and Presidents Dr. Lat Presidents			
Name : MRS. SUNITA	SHUKLA	el Lodis Die Leit Personalische Die Leit Per Die Lodi Personalische Die Lodi Personalische Hillerte Die Leit Personalische Die Lodi Per	Collected	: 21-9-2018 08:39 AM
Lab No. : 255899930	Age : 52 Yrs.	Gender : Female	Received Reported	: 21-9-2018 10:58 AM : 21-9-2018 01:37 PM
A/c Status :	Ref By: SELF ,	Gender . Female	Report Status	and a second second second
Test Name		Results	Units	Bio. Ref. Interva
LIVER & KIDNEY PANEL, S (Reflectance Photometry, Dir				
Urea		19.9	mg/dL	17.00 - 43.00
Creatinine		0.9	mg/dL	0.51 - 0.95
Uric Acid		3.4	mg/dL	2.60 - 6.00

(Hony) Brig. Dr. Arvind Lal M.B.B.S., D.C.P.

Padma Shri

	-	<b>J</b> *	
AST (SGOT)	44.0	U/L	< 35.00
ALT (SGPT)	47.0	U/L	< 35.00
GGTP	9.0	U/L	< 38.00
Alkaline Phosphatase (ALP)	97.0	U/L	30.00 - 120.00
Bilirubin, Total	0.4	mg/dL	0.30 - 1.20
Bilirubin, Direct	0.2	mg/dL	< 0.20
Bilirubin, Indirect	0.2	mg/dL	
Total Protein	8.80	g/dL	6.40 - 8.30
Albumin	4.30	g/dL	3.50 - 5.20
Globulins	4.5	g/dL	2.50 - 3.50
A/G Ratio	0.96 : 1		
Calcium	8.9	mg/dL	8.80 - 10.60
Phosphorus	4.0	mg/dL	2.40 - 4.40
Sodium	140.4	mEq/L	136.00 - 146.00
Potassium	4.79	mEq/L	3.50 - 5.10
Chloride	109.8	mEq/L	101.00 - 109.00

Dr.Surendra.K.Singh

Chief of Lab M.D. patho

Page 2 of 4

# Dr Lal PathLabs

National Reference Lab: Sector-18, Block-E, Rohini, New Delhi - 110 085 Tel: 011 - 3040-3210, Fax: 011 - 3040-3204 E-mail: lalpathlabs@lalpathlabs.com Web: www.lalpathlabs.com

L63 - LPL Sagar GROUND FLOOR,IN FRONT OF BUNDELKHAND MEDICAL COLLEGE, TILLI, NEAR GOUTAM TRADERS, SAGAR (M-P) 470001



#### Vandana Lat Dr. Vandana Lat M.D (PATH), IFCAP Chief of Pathology

Name : MRS. SUNITA SHUKLA			9-2018 08:39 AM
	and the Da La Paral de Da La Pa	reduced a De Las Participals De La	9-2018 10:58 AM
Lab No. : 255899930 Age : 52 Yrs.   A/c Status : Ref By: SELF ,	Gender : Female	Reported : 21-9 Report Status : Final	9-2018 01:37 PM
A/C Status : Rei By: SELF ,	Settleda Da Lat Particula Da Lat Pa	neport Status : Fille	ai
Test Name	Results	Units	Bio. Ref. Interva
COMPLETE BLOOD COUNT (CBC) (Electrical Impedence, Photometric)			
Hemoglobin	11.0	g/dL	11.50 - 15.00
PCV (Packed Cell Volume)	36.4	%	36.00 - 46.00
Total Leucocyte Count ( TLC )	4	thou/mm3	4.00 - 10.00
RBC Count	3.95	mill/mm3	3.80 - 4.80
MCV	92	fL	80.00 - 100.00
MCH	27.9	pg	27.00 - 32.00
MCHC	30.3	g/dL	32.00 - 35.00
RDW	12.7	%	11.50 - 14.50
Platelet Count	174	thou/mm3	150.00 - 450.00
Differential Leucocyte Count (DLC)			
Neutrophils	60	%	40.00 - 80.00
Lymphocytes	34	%	20.00 - 40.00
Monocytes	02	%	2.00 - 10.00
Eosinophils	04	%	1.00 - 6.00
Basophils	00	%	< 2.00
Absolute Leucocyte Count			

# Note

1. As per the recommendation of International council for Standardization in Hematology, the differential leucocyte counts are

additionally being reported as absolute numbers of each cell in per unit volume of blood.

2. Test conducted on EDTA whole blood.

# Dr Lal PathLabs

National Reference Lab: Sector-18, Block-E, Rohini, New Delhi - 110 085 Tel: 011 - 3040-3210, Fax: 011 - 3040-3204 E-mail: lalpathlabs@lalpathlabs.com Web: www.lalpathlabs.com

L63 - LPL Sagar GROUND FLOOR,IN FRONT OF BUNDELKHAND MEDICAL COLLEGE, TILLI, NEAR GOUTAM TRADERS, SAGAR (M-P) 470001



#### Vandana Lat Dr. Vandana Lat M.D (PATH), IFCAP Chief of Pathology

Name : MRS. SUNITA SHUKLA Lab No. : 255899930 Age : 52 Yrs.	Gender : Female	Received : 2	1-9-2018 08:39 AM 1-9-2018 10:58 AM 1-9-2018 01:37 PM
A/c Status : Ref By: SELF ,	Gender . Feinale	Report Status : F	and the second s
Test Name	Results	Units	Bio. Ref. Interval
LIPID SCREEN, SERUM (Reflectance Photometry, Calculated)			
Cholesterol, Total	113.0	mg/dL	<200.00
Triglycerides	126.0	mg/dL	<150.00
HDL Cholesterol	19.0	mg/dL	>50.00
LDL Cholesterol	69	mg/dL	<100.00
VLDL Cholesterol	25	mg/dL	<30.00
CHOL/HDL	5.95		
LDL/HDL	3.63		

# Interpretation

INTERPRETATION	TOTAL CHOLESTEROL		
	in mg/dL 	in mg/d∟ 	in mg/dL 
Optimal	< 200	< 150	< 100
Above Optimal			100 - 129
Borderline High	200 - 239	150 - 199	130 - 159
High	>= 240	200 - 499	160 - 189
Very High	-	>= 500	>= 190


# Note:

1. Measurements in the same patient can show physiological & analytical variations. Three serial samples 1 week

- apart are recommended for Total Cholesterol, Triglycerides, HDL& LDL Cholesterol.
- 2. NLA-2014 recommends a complete lipoprotein profile as the initial test for evaluating cholesterol.
- 3. Friedewald equation to calculate LDL cholesterol is most accurate when Triglyceride level is < 400 mg/dL. Measurement of Direct LDL cholesterol is recommended when Triglyceride level is > 400 mg/dL

Dr.Surendra.K.Singh Chief of Lab M.D. patho

----- End of report -----



\*Test results released pertain to the specimen submitted. \*All test results are dependent on the quality of the sample received by the Laboratory.\*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician. \*Sample repeats are accepted on request of Referring Physician within 7 days post reporting. \*Report delivery may be delayed due to unforeseencircumstances. Inconvenience is regretted. \*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit request within 72 hours post reporting. \*Test results may show interlaboratory variations. \*The Courts/Forum at Delhi shall have exclusive jurisdiction in all disputes/claims concerning the test(s) & or results of test(s). \*Test results are not valid for medico legal purposes.

\*Contact customer care Tel No. +91-11-39885050 for all queries related to test results.

Page 5 of 5